Pancreatic Cancer Metastatic

Also known as: Metastatic Pancreatic cancer / Metastatic Pancreatic Cancers / Pancreatic carcinoma metastatic / Metastases to pancreas / Malignant neoplasm of pancreas metastatic / Pancreas neoplasm malignant metastatic / Pancreatic metastasis

DrugDrug NameDrug Description
DB01101CapecitabineCapecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
DB00530ErlotinibErlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
DB00650LeucovorinFolinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. Despite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et al, 2009). As folate analogs, leucovorin and levoleucovorin are both used to counteract the toxic effects of folic acid antagonists, such as methotrexate, which act by inhibiting the enzyme dihydrofolate reductase (DHFR). They are indicated for use as rescue therapy following use of high-dose methotrexate in the treatment of osteosarcoma or for diminishing the toxicity associated with inadvertent overdosage of folic acid antagonists. Injectable forms are also indicated for use in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible and for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects associated with methotrexate therapy. As levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF), they are able to bypass DHFR reduction and act as a cellular replacement for the co-factor THF, thereby preventing these toxic side effects.
DrugDrug NamePhaseStatusCount
DB08916Afatinib1Active Not Recruiting1
DB08885Aflibercept1Completed1
DB11666Buparlisib1Completed1
DB12109CPI-6131Recruiting1
DB01101Capecitabine1Completed1
DB00530Erlotinib1Completed2
DB00099Filgrastim1Terminated1
DB00544Fluorouracil1Completed2
DB11911Galunisertib1Active Not Recruiting1
DB00441Gemcitabine1Active Not Recruiting2
DB00441Gemcitabine1Completed3
DB00441Gemcitabine1Recruiting2
DB00441Gemcitabine1Terminated1
DB00441Gemcitabine1Unknown Status1
DB12085LCL-1611Active Not Recruiting1
DB00650Leucovorin1Completed1
DB00526Oxaliplatin1Completed2
DB01229Paclitaxel1Active Not Recruiting2
DB01229Paclitaxel1Completed1
DB01229Paclitaxel1Recruiting2
DB08877Ruxolitinib1Terminated1
DB00112Bevacizumab1 / 2Not Yet Recruiting1
DB01101Capecitabine1 / 2Completed2
DB01101Capecitabine1 / 2Not Yet Recruiting1
DB00002Cetuximab1 / 2Completed1
DB11646Conatumumab1 / 2Completed1
DB11714Durvalumab1 / 2Not Yet Recruiting1
DB12342Ensituximab1 / 2Completed1
DB01590Everolimus1 / 2Completed1
DB00099Filgrastim1 / 2Completed1
DB00544Fluorouracil1 / 2Recruiting1
DB00441Gemcitabine1 / 2Active Not Recruiting1
DB00441Gemcitabine1 / 2Completed4
DB00441Gemcitabine1 / 2Recruiting2
DB00441Gemcitabine1 / 2Terminated1
DB12827Indoximod1 / 2Active Not Recruiting1
DB12154Itacitinib1 / 2Completed1
DB06043Olaratumab1 / 2Recruiting1
DB00526Oxaliplatin1 / 2Completed1
DB00526Oxaliplatin1 / 2Recruiting1
DB01229Paclitaxel1 / 2Active Not Recruiting1
DB01229Paclitaxel1 / 2Completed2
DB01229Paclitaxel1 / 2Recruiting1
DB01229Paclitaxel1 / 2Terminated1
DB05922Patidegib1 / 2Completed1
DB12655Patidegib1 / 2Completed1
DB09037Pembrolizumab1 / 2Active Not Recruiting1
DB07232Veliparib1 / 2Recruiting1
DB11703Acalabrutinib2Active Not Recruiting1
DB11703Acalabrutinib2Terminated1
DB00041Aldesleukin2Recruiting1
DB06013Aldoxorubicin2Not Yet Recruiting1
DB12378Apricoxib2Completed1
DB05971Archexin2Completed1
DB11945Avelumab2Not Yet Recruiting1
DB05136Bavituximab2Completed1
DB00112Bevacizumab2Completed1
DB00112Bevacizumab2Not Yet Recruiting1
DB00112Bevacizumab2Terminated1
DB01101Capecitabine2Completed2
DB01101Capecitabine2Not Yet Recruiting1
DB01101Capecitabine2Unknown Status1
DB00002Cetuximab2Completed1
DB00002Cetuximab2Terminated1
DB00515Cisplatin2Completed1
DB00531Cyclophosphamide2Completed1
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB01254Dasatinib2Active Not Recruiting1
DB00004Denileukin diftitox2Terminated1
DB01248Docetaxel2Completed1
DB00530Erlotinib2Completed4
DB00530Erlotinib2Unknown Status1
DB01073Fludarabine2Recruiting1
DB00544Fluorouracil2Active Not Recruiting1
DB00544Fluorouracil2Completed1
DB00544Fluorouracil2Not Yet Recruiting1
DB04901Galiximab2Completed1
DB00441Gemcitabine2Active Not Recruiting6
DB00441Gemcitabine2Completed11
DB00441Gemcitabine2Not Yet Recruiting2
DB00441Gemcitabine2Recruiting3
DB00441Gemcitabine2Terminated3
DB00441Gemcitabine2Unknown Status1
DB06186Ipilimumab2Recruiting1
DB00762Irinotecan2Completed1
DB00762Irinotecan2Recruiting1
DB04845Ixabepilone2Completed1
DB01259Lapatinib2Terminated1
DB00480Lenalidomide2Completed1
DB00650Leucovorin2Active Not Recruiting1
DB00650Leucovorin2Not Yet Recruiting1
DB00650Leucovorin2Recruiting1
DB00331Metformin2Completed1
DB09035Nivolumab2Recruiting1
DB00526Oxaliplatin2Active Not Recruiting1
DB00526Oxaliplatin2Completed1
DB00526Oxaliplatin2Not Yet Recruiting1
DB00526Oxaliplatin2Recruiting1
DB00526Oxaliplatin2Unknown Status1
DB01229Paclitaxel2Active Not Recruiting2
DB01229Paclitaxel2Completed1
DB00910Paricalcitol2Recruiting1
DB09037Pembrolizumab2Recruiting3
DB08828Vismodegib2Active Not Recruiting1
DB12109CPI-6133Not Yet Recruiting1
DB00758Clopidogrel3Active Not Recruiting1
DB00544Fluorouracil3Completed1
DB00441Gemcitabine3Completed1
DB00441Gemcitabine3Recruiting1
DB00441Gemcitabine3Terminated2
DB00762Irinotecan3Completed1
DB00762Irinotecan3Recruiting1
DB00650Leucovorin3Completed1
DB01229Paclitaxel3Completed1
DB00544FluorouracilNot AvailableRecruiting1
DB00441GemcitabineNot AvailableRecruiting1
DB00762IrinotecanNot AvailableRecruiting1
DB00650LeucovorinNot AvailableRecruiting1
DB01229PaclitaxelNot AvailableRecruiting1